IL1B and type 2 diabetes mellitus: In any case, the NLRP3 inflammasome represents an interesting starting point for the therapy of low-grade inflammation in obesity and the availability of clinical antagonists of IL-1β opens new possibilities for the therapy of T2DM and cardiovascular diseases in the context of obesity [199].